More recently, Erazo and colleagues found that ERK5 SUMOylation supports ERK5 nuclear trafficking, and stimulates, rather than inhibiting, ERK5-mediated transcriptional activation and cancer cell proliferation (Tatiana Erazo, Sergio Espinosa-Gil, Nora Diéguez-Martinez, Nestor Gomez and Jose M Lizcano; submitted for publication in IJMS, Special Issue “Targeting MAPK in Cancer”). Here, MAPK7 is linked to cancer.